Clinical Trial and Real-World Evidence Around CAR T-cell Therapy in LBCL

Video

Andrew Ip, MD, and Lori Leslie, MD, review clinical trial and real-world data on the efficacy and survival rates of CAR T-cell therapy in large B-cell lymphoma.

Related Videos
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Stacey Cohen, MD, an expert on colorectal cancer
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Related Content
Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.

Nanatinostat Combo Yields Responses in R/R EBV+ Peripheral T-Cell Lymphoma

April 18th 2024
Article

Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Unraveling Resistance and Heterogeneity in Mantle Cell Lymphoma Management

February 5th 2024
Podcast

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

April 14th 2024
Article

HR001 was found to have an efficacious response for patients with relapsed/refractory non-Hodgkin lymphoma.

Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.

Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

November 3rd 2022
Podcast

Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.

The regulatory agency sets a Prescription Drug User Fee Act date of August 13, 2024, for denileukin diftitox in relapsed/refractory cutaneous T-cell lymphoma.

FDA Accepts Resubmitted BLA for Denileukin Diftitox in R/R CTCL

March 19th 2024
Article

The regulatory agency sets a Prescription Drug User Fee Act date of August 13, 2024, for denileukin diftitox in relapsed/refractory cutaneous T-cell lymphoma.

FDA Approves Liso-Cel for Relapsed/Refractory CLL/SLL

FDA Approves Liso-Cel for Relapsed/Refractory CLL/SLL

March 15th 2024
Article

Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma can now receive lisocabtagene maraleucel after the FDA approved the drug, which was based on the phase 1/2 TRANSCEND CLL trial.